Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Total Liabilities (2018 - 2025)

10x Genomics' Total Liabilities history spans 8 years, with the latest figure at $245.0 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 17.52% year-over-year to $245.0 million; the TTM value through Dec 2025 reached $245.0 million, up 17.52%, while the annual FY2025 figure was $245.0 million, 17.52% up from the prior year.
  • Total Liabilities for Q4 2025 was $245.0 million at 10x Genomics, up from $242.2 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $245.0 million in Q4 2025 and bottomed at $190.4 million in Q3 2021.
  • The 5-year median for Total Liabilities is $206.2 million (2024), against an average of $210.2 million.
  • The largest annual shift saw Total Liabilities dropped 12.47% in 2021 before it rose 17.52% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $201.3 million in 2021, then rose by 10.92% to $223.2 million in 2022, then rose by 0.39% to $224.1 million in 2023, then decreased by 6.96% to $208.5 million in 2024, then increased by 17.52% to $245.0 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Total Liabilities are $245.0 million (Q4 2025), $242.2 million (Q3 2025), and $206.7 million (Q2 2025).